SCHEMBL6489388

SCHEMBL6489388

CCCCCOc1ccc(Cn2c(C)nc3c(C)cc(-c4nc(C)c(C(=O)OCC)[nH]4)cc32)c(Cl)c1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GABRA1 P14867 1/20 0.36
GABRG2 P18507 1/20 0.36
GABRB3 P28472 1/20 0.36
GABRA5 P31644 1/20 0.36
GABRA3 P34903 1/20 0.36
GABRA2 P47869 1/20 0.36
PPARG P37231 1/20 0.36
THRB P10828 2/20 0.34
PDE3B Q13370 1/20 0.34
PDE3A Q14432 1/20 0.34
P2RY12 Q9H244 1/20 0.34
DCTPP1 Q9H773 1/20 0.34
LMNA P02545 2/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
THRA P10827 1/20 0.33
PLA2G2A P14555 3/20 0.32
NPC1 O15118 1/20 0.32
RAB9A P51151 1/20 0.32
HSD17B10 Q99714 1/20 0.32
MAPT P10636 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6489425 0.92 PPARG (0.36) PPARGTHRBDCTPP1SMN1; SMN2THRA
SCHEMBL6488895 0.88 PPARG (0.44) GABRA1GABRG2GABRB3GABRA5GABRA3
SCHEMBL6489282 0.88 LMNA (0.44) GABRA2PPARGPDE3BPDE3ALMNA
SCHEMBL6491050 0.85 LMNA (0.38) GABRA2DCTPP1LMNASMN1; SMN2RAB9A
SCHEMBL6489090 0.84 PPARG (0.43) GABRA1GABRG2GABRB3GABRA5GABRA3
SCHEMBL6487238 0.84 PPARG (0.35) GABRA1GABRG2GABRB3GABRA5GABRA3
SCHEMBL6487942 0.81 MCL1 (0.42) PPARGTHRBPDE3BPDE3AP2RY12
SCHEMBL6497985 0.81 PPARG (0.36) PPARGTHRBDCTPP1SMN1; SMN2THRA
SCHEMBL6490173 0.81 RARB (0.47) PPARGDCTPP1
SCHEMBL6491906 0.80 PPARG (0.45) PPARGPDE3BPDE3AP2RY12SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050014812-A1 Benzimidazole compounds FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2005-01-20 US disclosed
WO-2004108686-A2 BENZIMIDAZOLE COMPOUNDS HAVING HYPOGLYCEMIC ACTIVITY FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2004-12-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050014812-A1 Benzimidazole compounds SLC5A1, SLC5A2, G6PD GABRA1 966/4885GABRG2 1437/4885GABRB3 1025/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.